Trials / Conditions / Hepatic Encephalopathy

Hepatic Encephalopathy

167 registered clinical trials studyying Hepatic Encephalopathy — 21 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE) NCT07528690	VA Office of Research and Development	Phase 2
Recruiting	Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis NCT07521332	Asian Institute Of Medical Sciences	Phase 4
Not Yet Recruiting	Evaluation of the Outcome of Fecal Microbiota Transplantation NCT07454408	Air Force Military Medical University, China	Phase 1 / Phase 2
Recruiting	The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) NCT07418008	University of Malaya	—
Terminated	A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Pat NCT06987968	Genfit	Phase 2
Recruiting	Affect of Melatonin on Sleep and Cognition in Cirrhosis NCT07046429	Weill Medical College of Cornell University	N/A
Not Yet Recruiting	Mechanisms of Perioperative Systemic Inflammation in the Development of PND in Cirrhotic Patients NCT07082946	Sichuan Provincial People's Hospital	—
Recruiting	Correlation Between Serum Albumin Level and Severity of Hepatic Encephalopathy in Patients With Chronic Liver NCT06953921	Sohag University	—
Recruiting	A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrh NCT06808074	Asian Institute of Gastroenterology, India	Phase 4
Recruiting	BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE NCT06538077	Post Graduate Institute of Medical Education and Research, Chandigarh	Phase 4
Not Yet Recruiting	Revealing Engagement Patterns Among Hepatic Encephalopathy Patients NCT06201988	Power Life Sciences Inc.	—
Completed	Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems NCT07480096	Indonesia University	Phase 2
Active Not Recruiting	Clinical Efficacy and Survival Prediction Analysis of Transjugular Intrahepatic Portosystemic Shunt in Patient NCT07437638	The Second Affiliated Hospital of Chongqing Medical University	—
Recruiting	Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy NCT06425380	Mayo Clinic	N/A
Completed	Metobolomics in the Characterisation of HE NCT06245473	Assistance Publique - Hôpitaux de Paris	—
Unknown	Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrh NCT06328088	Sir Ganga Ram Hospital	—
Unknown	Throid Dysfunction in Liver Failure and Its Eddects Upon Outcome NCT06179368	Assiut University	—
Unknown	Vegetable Proteins Versus Mixed Animal Proteins on the Outcome of Hepatic Encephalopathy NCT06075875	National Hepatology & Tropical Medicine Research Institute	N/A
Recruiting	Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement NCT06052176	Hunter Holmes Mcguire Veteran Affairs Medical Center	Phase 2
Unknown	Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening NCT06367127	Shanghai Changzheng Hospital	—
Unknown	Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy NCT06072521	Al-Azhar University	Phase 2
Withdrawn	Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver F NCT05772585	Assistance Publique - Hôpitaux de Paris	—
Unknown	Effectiveness of Oral Lactulose Versus Lactulose Enema in Hepatic Encephalopathy NCT05788627	Khyber Medical College, Peshawar	Phase 4
Completed	Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver NCT05754996	Cairo University	Phase 3
Unknown	The Efficacy and Safety of Rifaximin Treatment NCT05786859	Sun Yat-sen University	EARLY_Phase 1
Completed	Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF) NCT05700695	Post Graduate Institute of Medical Education and Research, Chandigarh	Phase 1
Unknown	Explore the Efficacy and Safety of FMT With Different Bacterial Doses in the Treatment of Hepatic Encephalopat NCT05669651	Hainv Gao	N/A
Unknown	Microbiota, Sarcopenia, and Hepatic Encephalopathy Change in Cirrhotic Patients Before and After Rehabilitatio NCT06040814	Chang Gung Memorial Hospital	N/A
Unknown	Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis NCT05511766	Tanta University	Phase 2 / Phase 3
Unknown	Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF NCT05421351	Post Graduate Institute of Medical Education and Research, Chandigarh	—
Completed	Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutio NCT05539027	Ain Shams University	Phase 4
Completed	Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration NCT05526404	Mayo Clinic	N/A
Active Not Recruiting	Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis NCT05297448	Bausch Health Americas, Inc.	Phase 3
Unknown	Role of Bilirubin Molecular Species in Hepatic Encephalopathy and Acute-on-chronic Liver Failure NCT05566548	Medica Sur Clinic & Foundation	—
Completed	Description of Lactulose Administration by Balloon Rectal Tube in Severe Hepatic Encephalopathy NCT06248736	University Hospital, Grenoble	—
Recruiting	Hepatic Encephalopathy Prevention With Polydextrose After TIPS: Pilot Study (POEME) NCT05206487	University Hospital, Toulouse	N/A
Completed	Effect of Brief Dietary Intervention on Ammonia Levels NCT05376488	Hunter Holmes Mcguire Veteran Affairs Medical Center	N/A
Active Not Recruiting	Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cir NCT05071716	Bausch Health Americas, Inc.	Phase 3
Unknown	Prediction of Post-TIPS Hepatic Encephalopathy in Patients With Liver Cirrhosis NCT05466669	Johannes Gutenberg University Mainz	—
Unknown	Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients NCT05279586	Madonna Magdy Fahmy	EARLY_Phase 1
Recruiting	TReatment for ImmUne Mediated PathopHysiology NCT04862221	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
Unknown	Efficacy and Safety of Fecal Microbiota Transplant for Secondary Prophylaxis of Hepatic Encephalopathy NCT05229289	Institute of Liver and Biliary Sciences, India	N/A
Completed	Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy NCT05070351	Duke University	Phase 1 / Phase 2
Unknown	Role of Sarcopenia and Nutritional/Physical Therapy Intervention in Post-TIPS Hepatic Encephalopathy NCT05346029	Anna Baiges	N/A
Unknown	Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2 NCT05140837	Hepatopancreatobiliary Surgery Institute of Gansu Province	—
Unknown	Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication NCT05128305	Qianfoshan Hospital	Phase 3
Withdrawn	MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function NCT04128462	Mallinckrodt	Phase 3
Completed	Speech in Hepatic Encephalopathy (HE) NCT05425316	University of Michigan	—
Completed	VE303 for Treatment of Hepatic Encephalopathy (HE) NCT04899115	Patricia Bloom	Phase 2
Terminated	Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy NCT04816916	Axcella Health, Inc	Phase 2
Completed	Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis NCT05033327	University of Alberta	N/A
Recruiting	Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment NCT06368895	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Phase 1
Terminated	Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy NCT04155099	Ochsner Health System	Phase 2
Completed	Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases NCT04698148	Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari	—
Completed	The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy. NCT04675775	University of Michigan	N/A
Unknown	Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HE NCT04317222	Third Affiliated Hospital, Sun Yat-Sen University	N/A
Unknown	Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial) NCT04436601	Aga Khan University	Phase 4
Withdrawn	HepQuant to Predict Hepatic Encephalopathy After TIPS NCT04664621	Northwestern University	N/A
Recruiting	Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose NCT04073290	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Phase 4
Enrolling By Invitation	Diagnosing Minimal Hepatic Encephalopathy NCT05433948	Esbjerg Hospital - University Hospital of Southern Denmark	—
Completed	Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF NCT04238416	Post Graduate Institute of Medical Education and Research, Chandigarh	Phase 1
Unknown	Flicker App for Minimal Hepatic Encephalopathy NCT04415294	University of Washington	—
Recruiting	Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy NCT04096014	The Cleveland Clinic	N/A
Completed	Rifamycin in Minimal Hepatic Encephalopathy NCT04082780	Hunter Holmes Mcguire Veteran Affairs Medical Center	Phase 2
Completed	FMT in Cirrhosis and Hepatic Encephalopathy NCT03796598	VA Office of Research and Development	Phase 1 / Phase 2
Recruiting	Safety and Efficacy of Fecal Microbiota Transplantation NCT04014413	Chinese University of Hong Kong	N/A
Unknown	The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy NCT03825848	Shanghai Zhongshan Hospital	N/A
Unknown	Role of MRI in Detection of Minimal Hepatic Encephalopathy NCT04131205	University Medical Centre Ljubljana	—
Unknown	Coenzyme Q10 and Meclofenoxate in Hepatic Encephalopathy NCT03961087	Zagazig University	N/A
Completed	A Study of MHE in Patients With Liver Diseases NCT04058327	Qin Ning	—
Recruiting	Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy NCT04161053	Tanta University	Phase 3
Completed	HEAL STUDY (Hepatic Encephalopathy and Albumin Study) NCT03585257	Hunter Holmes Mcguire Veteran Affairs Medical Center	Phase 2
Unknown	PEG3350 in ACLF With Hepatic Encephalopathy NCT03987893	Post Graduate Institute of Medical Education and Research, Chandigarh	Phase 4
Completed	Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial NCT03493204	University of Michigan	N/A
Active Not Recruiting	Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy NCT03420482	Massachusetts General Hospital	Phase 2
Completed	Minimal Hepatic Encephalopathy in Hereditary Hemorrhagic Telangiectasian NCT03586115	University of Bari	—
Unknown	Plasma Free Amino Acids in Patients With Hepatic Encephalopathy NCT03306498	Assiut University	—
Unknown	Diet Management on Hepatic Encephalopathy of Patients With Variceal Bleeding After Intrahepatic Portosystemic NCT03372499	Li Yang	N/A
Terminated	Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease NCT04940416	Stanford University	—
Completed	Oral Fecal Transplant in Cirrhosis NCT03152188	Virginia Commonwealth University	Phase 1
Unknown	PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy NCT03100513	Sherief Abd-Elsalam	Phase 4
Recruiting	VICIS - Vienna Cirrhosis Study NCT03267615	Medical University of Vienna	—
Completed	Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy NCT04787276	Bogomolets National Medical University	N/A
Completed	The Effect of Induced Hyperammonaemia on Sleep and Melanopsin-mediated Pupillary Light Response in Patients Wi NCT04771104	Rigshospitalet, Denmark	N/A
Unknown	Timing of Acute Palliative Care Consultation in Critically Ill Patients NCT02858778	Wayne State University	N/A
Completed	Fecal Transplant for Hepatic Encephalopathy NCT03439982	University of Alberta	Phase 1 / Phase 2
Unknown	The International Imaging Registry in Liver Cirrhosis (BAVENO-VI SPSS GROUP). NCT02692430	Hospital Universitari Vall d'Hebron Research Institute	—
Completed	A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Ret NCT02377947	Abbott	—
Completed	Minimal HePatic Encephalopathy Among CiRrhotics. A Cross SEctional, Clinico-EpidEmiological, Multi-Centre, Stu NCT02613858	Abbott	—
Completed	Fecal Transplant in Recurrent Hepatic Encephalopathy NCT02636647	Jasmohan Bajaj	Phase 1
Withdrawn	A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure NCT02086825	NYU Langone Health	Phase 3
Completed	Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER) NCT02488993	Norgine	—
Unknown	Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy NCT02401490	Hospital Universitari Vall d'Hebron Research Institute	Phase 4
Unknown	Metformin Experience on Minimal Hepatic Encephalopathy NCT02470546	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Phase 4
Completed	Microbial Resistance of Rifaximin in Hepatic Encephalopathy NCT04736836	National Hepatology & Tropical Medicine Research Institute	Phase 4
Unknown	The Effects of Nitazoxanide in Hepatic Encephalopathy NCT02334163	Ain Shams University	Phase 2
Unknown	Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota in Cirrhotic Patients NCT02427906	West China Hospital	—
Completed	Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study NCT02255617	University of Alberta	Phase 1 / Phase 2
Completed	Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Varic NCT02158182	Hospital General de Mexico	Phase 4
Withdrawn	Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS NCT02048969	Yale University	Phase 1 / Phase 2
Completed	Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy NCT02163837	Centre Hospitalier Universitaire Saint Pierre	N/A
Completed	Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalop NCT01966419	Ocera Therapeutics, Inc.	Phase 2
Unknown	Quantitative Determination of Brain Water Content in Patients During and After Hepatic Encepalopathy NCT02177708	University of Aarhus	—
Completed	L-ornithine L-aspartate in Overt Hepatic Encephalopathy NCT01722578	Dayanand Medical College and Hospital	Phase 4
Completed	Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate NCT01847651	Imperial College London	Phase 4
Terminated	Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt NCT02026609	University of Arkansas	—
Terminated	Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Enc NCT01846663	Bausch Health Americas, Inc.	Phase 4
Terminated	Quality of Life and Nutritional Improvements in Cirrhotic Patients NCT01842113	Tampa General Hospital	Phase 4
Unknown	ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventio NCT01798329	A.O. Ospedale Papa Giovanni XXIII	Phase 3
Withdrawn	Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.) NCT01923376	New York Presbyterian Brooklyn Methodist Hospital	N/A
Completed	The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic En NCT01842581	Bausch Health Americas, Inc.	Phase 4
Completed	iPod Games in Hepatic Encephalopathy NCT02154282	Hunter Holmes Mcguire Veteran Affairs Medical Center	N/A
Completed	Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome NCT02083367	OSF Healthcare System	—
Completed	Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement NCT01773538	Mette Munk Lauridsen	N/A
Withdrawn	Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy NCT01882855	NYU Langone Health	—
Terminated	The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. NCT01846806	NYU Langone Health	N/A
Completed	Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy NCT01559519	University of Roma La Sapienza	Phase 4
Unknown	Efficacy of Sildenafil in the Improvement of Cognition and Quality of Life in Patients With Cirrhosis of Liver NCT02028429	Post Graduate Institute of Medical Education and Research, Chandigarh	Phase 1 / Phase 2
Terminated	Factors Associated With End Stage Liver Disease NCT01846819	NYU Langone Health	—
Withdrawn	The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis NCT01777971	NYU Langone Health	—
Unknown	Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance Imaging NCT01434056	Hospital Israelita Albert Einstein	—
Completed	S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE NCT01446523	Govind Ballabh Pant Hospital	N/A
Completed	Effect of Tolvaptan on Cognitive Function in Cirrhosis NCT01556646	Hunter Holmes Mcguire Veteran Affairs Medical Center	Phase 3
Completed	Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive Care NCT01494064	Assistance Publique - Hôpitaux de Paris	—
Completed	Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With NCT01283152	University of Texas Southwestern Medical Center	N/A
Completed	Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients NCT02017119	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	Phase 2
Unknown	Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics NCT01356121	Govind Ballabh Pant Hospital	Phase 4
Completed	Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Ra NCT01218568	Institute of Liver and Biliary Sciences, India	N/A
Completed	Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of Hepatic Ence NCT01151475	University of Aarhus	—
Terminated	Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy NCT01113567	Coordinación de Investigación en Salud, Mexico	N/A
Completed	Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation NCT01110447	CD Pharma India Pvt. Ltd.	Phase 2 / Phase 3
Completed	Cerebrovascular Reactivity in Hepatic Encephalopathy NCT01099293	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	—
Completed	Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal NCT01059396	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Phase 4
Completed	A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy NCT00999167	Amgen	Phase 2
Completed	Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. NCT01041755	Centro Regional para el Estudio de las Enfermedades Digestivas	Phase 4
Completed	Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life NCT01008293	CD Pharma India Pvt. Ltd.	Phase 2 / Phase 3
Completed	Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis NCT00886925	Hospital Universitari Vall d'Hebron Research Institute	Phase 4
Completed	Bioelectrical Impedance Vector Analysis in Cirrhotic Patients NCT01603953	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	—
Unknown	Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy NCT00896831	Hospital de Clinicas de Porto Alegre	Phase 4
Unknown	Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis NCT01178372	Govind Ballabh Pant Hospital	Phase 4
Completed	Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy NCT00740142	Mahidol University	Phase 4
Completed	A Study of Controlled Lactulose Withdrawal NCT00914056	Hunter Holmes Mcguire Veteran Affairs Medical Center	N/A
Completed	Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Trans NCT00839358	Hospital Clinic of Barcelona	Phase 4
Unknown	Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy NCT01097811	UPECLIN HC FM Botucatu Unesp	N/A
Unknown	Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis NCT01175538	Govind Ballabh Pant Hospital	Phase 4
Terminated	Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy NCT00597909	Amgen	Phase 2
Completed	Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subj NCT00931060	University of Aarhus	N/A
Completed	Rifaximin in Minimal Hepatic Encephalopathy NCT00533910	Hunter Holmes Mcguire Veteran Affairs Medical Center	N/A
Completed	Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy NCT00558038	Ocera Therapeutics	Phase 2
Completed	Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy NCT00686920	Bausch Health Americas, Inc.	Phase 3
Completed	The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure NCT00655304	Rigshospitalet, Denmark	N/A
Completed	Brain Energy Metabolism in Patients With Chronic Liver Disease and Impaired Central Nervous System NCT00424957	University of Aarhus	—
Completed	A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Con NCT00986895	Amgen	Phase 1
Terminated	RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial NCT00364689	University of Miami	Phase 3
Completed	Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment. NCT00305591	Imperial College London	N/A
Completed	A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy NCT00298038	Bausch Health Americas, Inc.	Phase 3
Completed	Neuromonitoring of Hepatic Encephalopathy NCT01878305	University of Helsinki	—
Unknown	The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy NCT00281502	Weill Medical College of Cornell University	Phase 2
Completed	Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life NCT00375375	Post Graduate Institute of Medical Education and Research, Chandigarh	Phase 4
Completed	Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy NCT00433368	Aga Khan University	Phase 3
Terminated	Manganese in Women With Encephalopathy NCT00985010	Materno-Perinatal Hospital of the State of Mexico	—
Completed	Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy NCT00955500	Hospital Universitari Vall d'Hebron Research Institute	Phase 4
Completed	Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy NCT01223742	University of Catania	N/A
Completed	Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recir NCT00287235	Vantive Health LLC	N/A
Completed	N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure NCT00248625	University of Pittsburgh	Phase 3
Completed	A Multi-Center Group to Study Acute Liver Failure in Children NCT00986648	University of Pittsburgh	—
Completed	Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis NCT00004796	National Center for Research Resources (NCRR)	Phase 2